慢性血栓栓塞性肺动脉高压和慢性血栓栓塞性肺疾病

黄伸伸; 邱家勇; 毛毅敏

doi:10.12376/j.issn.2097-0501.2023.01.003

慢性血栓栓塞性肺动脉高压和慢性血栓栓塞性肺疾病

doi: 10.12376/j.issn.2097-0501.2023.01.003

黄伸伸¹,
邱家勇^{1, 2},
毛毅敏^1, ,

1.
河南科技大学第一附属医院呼吸与危重症医学科，洛阳 471000
2.
河北医科大学第二医院呼吸与危重症医学科，石家庄 050000

基金项目:

河南省自然科学基金 182300410365

详细信息

通信作者:
毛毅敏，E-mail: 1419295143qq.com

中图分类号: R544.1;R563.5
计量
- 文章访问数: 29
- HTML全文浏览量: 5
- PDF下载量: 4
- 被引次数: 0
出版历程
- 收稿日期: 2022-12-08
- 修回日期: 2022-12-31
- 网络出版日期: 2023-03-07

Chronic Thromboembolic Pulmonary Hypertension and ChronicThromboembolic Pulmonary Disease

HUANG Shenshen¹,
QIU Jiayong^{1, 2},
MAO Yimin^{1
, ,}

1.
Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471000, China
2.
Department of Respiratory and Critical Care Medicine, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, China

Funding:

The Natural Science Foundation of Henan Province 182300410365

More Information

Corresponding author: MAO Yimin, E-mail: 1419295143qq.com

摘要

摘要: 慢性血栓栓塞性肺动脉高压(CTEPH)和慢性血栓栓塞性肺疾病(CTEPD)是急性肺栓塞后因肺动脉内血栓残留、机化，伴或不伴肺动脉高压(PH)的一类疾病。随着诊疗的不断进步、综合治疗策略的观念更新，使这类疾病的预后得到极大改善。但医务人员对这类疾病认识不足，且中国缺少流行病学数据，发病机制未明，具有非特异性临床表现。因此，在临床上易误诊、漏诊和延迟诊断。为了加强医务工作者对其认识，本文对CTEPH和CTEPD的定义、流行病学、病理、发病机制、诊断和治疗等方面予以归纳总结。
- 慢性血栓栓塞性肺动脉高压 /
- 慢性血栓栓塞性肺疾病 /
- 肺血栓栓塞症
Abstract: Chronic thromboembolic pulmonary hypertension (CTEPH) and chronic thromboembolic pulmonary disease (CTEPD) are diseases that occur after acute pulmonary embolism resulting from residual and organized intra-pulmonary thrombus, with or without pulmonary hypertension(PH). The prognosis of these diseases has been dramatically improved with the continuous progress of treatment and the updated concept of the comprehensive treatment strategy. However, there is a lack of awareness of these diseases among medical practitioners, and a lack of epidemiological data in China, with unknown pathogenesis and non-specific clinical manifestations. Therefore, it is easy to misdiagnosis, underdiagnosis and delay diagnosis in clinical practice. To enhance the understanding of medical personnel, this paper summarizes the definition, epidemiology, pathology, pathogenesis, diagnosis and treatment of CTEPH and CTEPD.
- chronic thromboembolic pulmonary hypertension /
- chronic thromboembolic pulmonary disease /
- pulmonary thromboembolism
注释:

作者贡献：黄伸伸、邱家勇负责综述文献检索、分析和论文撰写；毛毅敏负责论文选题、分析、润色和修改。

利益冲突：所有作者均声明不存在利益冲突。

HTML全文

图 1 疑诊肺动脉高压的诊断策略

^a警告信号包括症状进展迅速、运动耐量严重减弱、轻度运动时出现晕厥前症状或晕厥、右心衰竭的迹象；^bCTEPH危险因素：PTE病史、永久性血管内装置、炎症性肠病、原发性血小板增多症、脾切除术、大剂量甲状腺激素替代疗法及恶性肿瘤；PH：肺动脉高压；PAH：动脉型肺动脉高压；NT-proBNP：N端脑钠肽前体；CTEPH：慢性血栓栓塞性肺动脉高压；CTPA：CT肺动脉造影

Figure 1. Diagnostic strategy of suspected pulmonary hypertension (PH)

下载: 全尺寸图片幻灯片

图 2 肺血栓栓塞症(PTE)后慢性血栓栓塞性肺疾病(CTEPD)和慢性血栓栓塞性肺动脉高压(CTEPH)的诊断策略

V/Q：核素肺灌注显像；RHC：静息状态下右心导管检查

Figure 2. Diagnostic strategies of chronic thrombo-embolic pulmonary disease(CTEPD) and chronic thromboembolic pulmonary hypertension(CTEPH) after pulmonary thromboembolism(PTE)

下载: 全尺寸图片幻灯片

图 3 Leiden CTEPH排除流程

右心室压力过载的心电图标准: 1.V1导联rSR′或rSr′; 2.V1导联R∶S＞1，伴有R＞0.5 mV; 3.QRS轴＞90 °

Figure 3. Leiden CTEPH exclusion process

下载: 全尺寸图片幻灯片

参考文献(49)

[1]	Nijkeuter M, Hovens MM, Davidson BL, et al. Resolution of thromboemboli in patients with acute pulmonary embolism: a systematic review[J]. Chest, 2006, 129(1): 192-197. doi: 10.1378/chest.129.1.192
[2]	Tavoly M, Wik HS, Sirnes PA, et al. The impact of post-pulmonary embolism syndrome and its possible determinants[J]. Thromb Res, 2018, 171: 84-91. doi: 10.1016/j.thromres.2018.09.048
[3]	Sista AK, Klok FA. Late outcomes of pulmonary embolism: the post-PE syndrome[J]. Thromb Res, 2018, 164: 157-162. doi: 10.1016/j.thromres.2017.06.017
[4]	Klok FA, van der Hulle T, den Exter PL, et al. The post-PE syndrome: a new concept for chronic complications of pulmonary embolism[J]. Blood Rev, 2014, 28(6): 221-226. doi: 10.1016/j.blre.2014.07.003
[5]	Klok FA, Tijmensen JE, Haeck ML, et al. Persistent dyspnea complaints at long-term follow-up after an episode of acute pulmonary embolism: results of a questionnaire[J]. Eur J Intern Med, 2008, 19(8): 625-629. doi: 10.1016/j.ejim.2008.02.006
[6]	Delcroix M, Torbicki A, Gopalan D, et al. ERS statement on chronic thromboembolic pulmonary hypertension[J]. Eur Respir J, 2021, 57(6): 2002828. doi: 10.1183/13993003.02828-2020
[7]	Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Heart J, 2022, 43(38): 3618-3731. doi: 10.1093/eurheartj/ehac237
[8]	中华医学会呼吸病学分会肺栓塞与肺血管病学组, 中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会, 全国肺栓塞与肺血管病防治协作组, 等. 中国肺动脉高压诊断与治疗指南(2021版)[J]. 中华医学杂志, 2021, 101(1): 11-51. doi: 10.3760/cma.j.cn112137-20201008-02778
[9]	Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension[J]. Eur Respir J, 2019, 53(1): 1801913. doi: 10.1183/13993003.01913-2018
[10]	Le Gal G, Carrier M, Castellucci LA, et al. Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official communication from the SSC of the ISTH[J]. J Thromb Haemost, 2021, 19(1): 297-303. doi: 10.1111/jth.15138
[11]	van Kan C, van der Plas MN, Reesink HJ, et al. Hemodynamic and ventilatory responses during exercise in chronic thromboembolic disease[J]. J Thorac Cardiovasc Surg, 2016, 152(3): 763-771. doi: 10.1016/j.jtcvs.2016.05.058
[12]	Taboad AD, Pepke-Zaba J, Jenkins DP, et al. Outcome of pulmonary endarterectomy in symptomatic chronic thromboembolic disease[J]. Eur Respir J, 2014, 44(6): 1635-1645. doi: 10.1183/09031936.00050114
[13]	Mccabe C, Preston SD, Gopalan D, et al. Cardiopulmonary exercise testing suggests a beneficial response to pulmonary endarterectomy in a patient with chronic thromboembolic obstruction and normal preoperative pulmonary hemodynamics[J]. Pulm Circ, 2014, 4(1): 137-141. doi: 10.1086/674878
[14]	Held M, Kolb P, Grun M, et al. Functional characterization of patients with chronic thromboembolic disease[J]. Respiration, 2016, 91(6): 503-509. doi: 10.1159/000447247
[15]	Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review[J]. Pulm Circ, 2021, 11(1): 2045894020977300.
[16]	Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry[J]. Circulation, 2011, 124(18): 1973-1981. doi: 10.1161/CIRCULATIONAHA.110.015008
[17]	Lang IM, Madani M. Update on chronic thromboembolic pulmonary hypertension[J]. Circulation, 2014, 130(6): 508-518. doi: 10.1161/CIRCULATIONAHA.114.009309
[18]	Yu Y, Yang L, Zhang Y, et al. Incidence and risk factors of chronic thromboembolic pulmonary hypertension in patients with diagnosis of pulmonary embolism for the first time in real world[J]. Clin Respir J, 2018, 12(11): 2551-2558. doi: 10.1111/crj.12955
[19]	Dzikowska-diduch O, Kostrubiec M, KurnickA K, et al. The post-pulmonary syndrome-results of echocardiographic driven follow up after acute pulmonary embolism[J]. Thromb Res, 2020, 186: 30-35. doi: 10.1016/j.thromres.2019.12.008
[20]	Klok FA, Barco S, Konstantinides SV, et al. Determinants of diagnostic delay in chronic thromboembolic pulmonary hypertension: results from the European CTEPH Registry[J]. Eur Respir J, 2018, 52(6): 1801687. doi: 10.1183/13993003.01687-2018
[21]	Boon G, Ende-verhaar YM, Bavalia R, et al. Non-invasive early exclusion of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: the InShape Ⅱ study[J]. Thorax, 2021, 76(10): 1002-1009. doi: 10.1136/thoraxjnl-2020-216324
[22]	Jeong I, Fernandes T, Alotaibi M, et al. Direct oral anticoagulant use and thrombus detection in patients with chronic thromboembolic pulmonary hypertension referred for pul-monary thromboendarterectomy[J]. 2019, 54(suppl 63): OA5161.
[23]	Barati S, Amini H, Ahmadi ZH, et al. Evaluating the efficacy and safety of rivaroxaban as a warfarin alternative in chronic thromboembolic pulmonary hypertension patients undergoing pulmonary endarterectomy: a randomized clinical trial[J]. Rev Port Cardiol, 2022, S0870-2551(22)00458-9.
[24]	Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)[J]. Eur Heart J, 2016, 37(1): 67-119. doi: 10.1093/eurheartj/ehv317
[25]	Quadery SR, Swift AJ, Billings CG, et al. The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension[J]. Eur Respir J, 2018, 52(3): 1800589. doi: 10.1183/13993003.00589-2018
[26]	Lankeit M, Krieg V, Hobohm L, et al. Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension[J]. J Heart Lung Transplant, 2017. doi: 10.1016/j.healun.2017.06.011.
[27]	Madani MM, Auger WR, Pretorius V, et al. Pulmonary endarterectomy: recent changes in a single institution's experience of more than 2, 700 patients[J]. Ann Thorac Surg, 2012, 94(1): 97-103. doi: 10.1016/j.athoracsur.2012.04.004
[28]	D'armini AM, Morsolini M, Mattiucci G, et al. Pulmonary endarterectomy for distal chronic thromboembolic pulmonary hypertension[J]. J Thorac Cardiovasc Surg, 2014, 148(3): 1005-1011. doi: 10.1016/j.jtcvs.2014.06.052
[29]	Hsieh WC, Jansa P, Huang WC, et al. Residual pulmonary hypertension after pulmonary endarterectomy: A meta-analysis[J]. J Thorac Cardiovasc Surg, 2018, 156(3): 1275-1287. doi: 10.1016/j.jtcvs.2018.04.110
[30]	Tsuji A, Ogo T, Demachi J, et al. Rescue balloon pulmonary angioplasty in a rapidly deteriorating chronic thromboembolic pulmonary hypertension patient with liver failure and refractory infection[J]. Pulm Circ, 2014, 4(1): 142-147. doi: 10.1086/675643
[31]	Collaud S, Brenot P, Mercier O, et al. Rescue balloon pulmonary angioplasty for early failure of pulmonary endarterectomy: the earlier the better?[J]. Int J Cardiol, 2016, 222: 39-40. doi: 10.1016/j.ijcard.2016.07.021
[32]	Khan MS, Amin E, Memon MM, et al. Meta-analysis of use of balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension[J]. Int J Cardiol, 2019, 291: 134-139. doi: 10.1016/j.ijcard.2019.02.051
[33]	Inami T, Kataoka M, Yanagisawa R, et al. Long-term outcomes after percutaneous transluminal pulmonary angioplasty for chronic thromboembolic pulmonary hypertension[J]. Circulation, 2016, 134(24): 2030-2032. doi: 10.1161/CIRCULATIONAHA.116.024201
[34]	Kataoka M, Inami T, Kawakami T, et al. Balloon pulmonary angioplasty (percutaneous transluminal pulmonary angioplasty) for chronic thromboembolic pulmonary hypertension: a Japanese perspective[J]. JACC Cardiovasc Interv, 2019, 12(14): 1382-1388. doi: 10.1016/j.jcin.2019.01.237
[35]	Hu S, Tan JS, Liu S, et al. The long-term survival in patients with chronic thromboembolic pulmonary hypertension: experience from a single center in China[J]. J Thromb Thrombolysis, 2022, 53(4): 926-933. doi: 10.1007/s11239-021-02594-1
[36]	Taniguchi Y, Miyagawa K, Nakayama K, et al. Balloon pulmonary angioplasty: an additional treatment option to improve the prognosis of patients with chronic thromboem-bolic pulmonary hypertension[J]. EuroIntervention, 2014, 10(4): 518-525. doi: 10.4244/EIJV10I4A89
[37]	Simonneau G, D'armini AM, Ghofrani HA, et al. Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial[J]. Lancet Respir Med, 2016, 4(5): 372-380. doi: 10.1016/S2213-2600(16)30022-4
[38]	Ghofrani HA, D'armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension[J]. N Engl J Med, 2013, 369(4): 319-329. doi: 10.1056/NEJMoa1209657
[39]	Sadushi-kolici R, Jansa P, Kopec G, et al. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial[J]. Lancet Respir Med, 2019, 7(3): 239-248. doi: 10.1016/S2213-2600(18)30367-9
[40]	Kim NH, Papamatheakis DG, Fernandes TM. Evolution of randomized, controlled studies of medical therapy in chronic thromboembolic pulmonary hypertension[J]. Pulm Circ, 2021, 11(2): 20458940211007373.
[41]	Ghofrani HA, Simonneau G, D'armini AM, et al. Maciten-tan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study[J]. Lancet Respir Med, 2017, 5(10): 785-794. doi: 10.1016/S2213-2600(17)30305-3
[42]	Ogo T, Shimokawahara H, Kinoshita H, et al. Selexipag for the treatment of chronic thromboembolic pulmonary hypertension[J]. Eur Respir J, 2022, 60(1): 2101694. doi: 10.1183/13993003.01694-2021
[43]	Jais X, Brenot P, Bouvaist H, et al. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study[J]. Lancet Respir Med, 2022, 10(10): 961-971. doi: 10.1016/S2213-2600(22)00214-4
[44]	Guth S, D'armini AM, Delcroix M, et al. Current strategies for managing chronic thromboembolic pulmonary hyperten-sion: results of the worldwide prospective CTEPH Registry[J]. ERJ Open Res, 2021, 7(3): 00850-2020.
[45]	Reesink HJ, Surie S, Kloek JJ, et al. Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension[J]. J Thorac Cardiovasc Surg, 2010, 139(1): 85-91. doi: 10.1016/j.jtcvs.2009.03.053
[46]	Cannon JE, Su L, Kiely DG, et al. Dynamic risk stratification of patient long-term outcome after pulmonary endarterectomy: results from the united kingdom national cohort[J]. Circulation, 2016, 133(18): 1761-1771. doi: 10.1161/CIRCULATIONAHA.115.019470
[47]	Capone C, Valentini A, Spinillo SL, et al. Radiological differences between chronic thromboembolic pulmonary disease (CTEPD) and chronic thromboembolic pulmonary hypertension (CTEPH)[J]. Eur Radiol, 2021, 31(8): 6230-6238. doi: 10.1007/s00330-020-07556-4
[48]	Wiedenroth CB, Olsson KM, Guth S, et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic disease[J]. Pulm Circ, 2018, 8(1): 2045893217753122.
[49]	Inami T, Kataoka M, Kikuchi H, et al. Balloon pulmonary angioplasty for symptomatic chronic thromboembolic disease without pulmonary hypertension at rest[J]. Int J Cardiol, 2019, 289: 116-118. doi: 10.1016/j.ijcard.2019.04.080